

# Salix Pharma will buy Santarus for \$2.12 billion

November 7 2013

---

Salix Pharmaceuticals will buy Santarus for about \$2.12 billion to add to its roster of drugs.

Salix will pay \$32 per share for Santarus' stock, the drugmakers said Thursday. They say the deal values Santarus at \$2.6 billion.

Salix Pharmaceuticals Ltd., based in Raleigh, N.C., is paying a 38 percent premium to Santarus Inc.'s closing price of \$23.22 Thursday.

The boards of both companies have approved the deal and say they expect the sale to close during the first quarter.

Salix sells Xifaxan, a treatment for traveler's diarrhea and [neurological problems](#) associated with [liver failure](#), the ulcerative colitis drug Apriso, and constipation drug Relistor.

San Diego-based Santarus, whose stock price has more than doubled this year, sells Glumetza for diabetes, Zegerid for [acid reflux](#), and Uceris for ulcerative colitis.

© 2013 The Associated Press. All rights reserved.

Citation: Salix Pharma will buy Santarus for \$2.12 billion (2013, November 7) retrieved 2 May 2024 from <https://medicalxpress.com/news/2013-11-salix-pharma-santarus-billion.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private
---

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.